hematology - myeloid gene panels

Lab Test name Contact Comments
UZ Leuven MolPLUZ hematology - myeloid gene panels Lucienne Michaux / Els Lierman
Sample type: blood / bone marrow (EDTA, 2-5 ml)
Frequency: 1x/week
Test type: TruSight Myeloid (Illumina), NGS
Genes: ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, IDH1, IDH2, IKZF1, JAK2, KDM6A, KIT, KRAS, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
Accredited:
UZ Gent hematology - myeloid gene panels Karl Vandepoele,
Joni Van Der Meulen,
Barbara Denys
In-house developed NGS panel to screen clinically relevant genes in AML/MDS:
ASXL1, CEBPA, DNMT3A, EZH2, FLT3, IDH1, IDH2, KIT, NPM1, NRAS, RUNX1, SF3B1, SRSF2, TET2, TP53, U2AF1, WT1
1x/week
Version date: 18/09/2018
Accredited:
UZ Gent hematology - myeloid gene panels Karl Vandepoele,
Joni Van Der Meulen,
Barbara Denys
In-house developed NGS panel to screen clinically relevant genes in MPN and MDS/MPN overlap:
CALR, CSF3R, JAK2, MPL, SETBP1 and SRSF2
1x/week

Also available in a cost-effective mini-panel: JAK2, CALR and MPL
Version date: 16/08/2017
Accredited:
CHU Liège - Hemato hematology - myeloid gene panels Dr Frédéric LAMBERT
NGS targeted sequencing after hybridization capture, Home brew assay; ISO15189 accreditation from BELAC.
Targets: SH2B3 (LNK); CBL; ASXL1; CALR; CSF1R; CSF3R; DNMT3A; EPOR; ETNK1; EZH2; JAK1; JAK2; JAK3; KIT; MPL; NF1; PHD2; SETBP1; SRSF2; STAT5B; TET2; U2AF35; VHL; ZRSR2; BCROR; BCORL1
Full genes list available upon request.

Indications:

- MDS diagnosis if >= 1 lineage with > 10% of dysplasia BUT not all WHO criteria met; persistent, unexplained (pan)-cytopenia (>3-6 months)
- AML diagnosis & prognostication;
- Triple-negative MPNs;
- CMML & others "Overlap syndromes" diagnosis;
- Atypical/Phi-negative MPNs;
CHU Liège - Hemato hematology - myeloid gene panels Dr Frédéric LAMBERT
Familial MDS/AML syndromes; Inheritred bone marrow failure syndromes (IBMFS):
Familial platelet disorder with propensy to myeloid malignancies (RUNX1); Thrombocytopenia 2 (ANKRD26); Familial AML with CEBPA; Familial AML with DDX41; Thrombocythopenia 5 (ETV6); Familial MDS/AML with mutated GATA2; Telomere syndromes (DC); Familial aplastic anemia with SRP72 mutation; Li-Fraumeni syndrome (Therapy related disorders)

NGS targeted sequencing after hybridization capture, Home brew assay; ISO15189 accreditation from BELAC.

INFORMED CONSENT REQUESTED BEFORE TESTING:
http://www.chu.ulg.ac.be/jcms/c_10919499/formulaire-de-consentement-ngs
AZ St-Jan Brugge - Laboratoriumgeneeskunde hematology - myeloid gene panels Helena Devos/Friedel Nollet
Qiagen GeneRead custom panel. Genes : ASXL1; CALR; CSF3R; DNMT3A; FLT3; IDH1; IDH2; JAK2; KIT; MPL; NPM1; RUNX1; SETBP1; SF3B1; SRSF2; TET2; TP53; U2AF1; WT1.
Version date: 12/09/2017
Accredited:
Jessa Hospital hematology - myeloid gene panels Guy Froyen
custom panel with 49 genes based on Ts Myeloid (Illumina)
2x/week
on MiSeq
Version date: 13/11/2017
Accredited:
AZ Delta hematology - myeloid gene panels Geert Martens, Elke Boone
Sample type: blood / bone marrow (300µl - 1 ml)
Frequency: 1x/month
Test type: TruSight Myeloid (Illumina), NGS
Genes: ABL1, ASXL1, ATRX, BCOR, BCORL1, BRAF, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CSF3R, CUX1, DNMT3A, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, HRAS, IDH1, IDH2, IKZF1, JAK2, JAK3, KDM6A, KIT, KRAS, KMT2A, MPL, MYD88, NOTCH1, NPM1, NRAS, PDGFRA, PHF6, PTEN, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1, ZRSR2
Version date: 05/12/2017
Accredited: